Double-drug development against antioxidant enzymes from Plasmodium falciparum

Redox Report

Volumn 8, Issue 5, 2003, Pages 280-283

  Biot, Christophe ^a,c   Dessolin, Jean ^a,d   Grellier, Philippe ^b   Davioud Charvet, Elisabeth ^a,e  

^a UNIV LILLE   (France)

^b MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d INSTITUT EUROPÉEN DE CHIMIE ET BIOLOGIE   (France)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

10 (3',5' DICHLOROPHENYL) 3 METHYLISOALLOXAZINE; 4 AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; ANTIOXIDANT; CHLOROQUINE; DITHIOL DERIVATIVE; ESTER DERIVATIVE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE REDUCTASE; GLUTATHIONE REDUCTASE INHIBITOR; HEME; HEXANOIC ACID DERIVATIVE; MENADIONE; METHYLENE BLUE; NAPHTHAZARIN; NEW DRUG; OXIDOREDUCTASE INHIBITOR; PRODRUG; REACTIVE OXYGEN METABOLITE; TETRAZOLE DERIVATIVE; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMALARIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DETOXIFICATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ERYTHROCYTE; GLUTATHIONE METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALARIA; NONHUMAN; OXIDATION REDUCTION STATE; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; ANTIOXIDANTS; CHLOROQUINE; DRUG RESISTANCE; ENZYME INHIBITORS; ERYTHROCYTES; GLUTATHIONE; GLUTATHIONE REDUCTASE; HEME; HUMANS; MALARIA, FALCIPARUM; MICE; PLASMODIUM FALCIPARUM; PRODRUGS; SULFHYDRYL COMPOUNDS; THIOREDOXIN REDUCTASE (NADPH);

PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM;

EID: 0346398299     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100003225002916     Document Type: Article

References (20)

1. Atamna H, Ginsburg H. Heme degradation in the presence of glutathione. A proposed mechanism to account for the high levels of non-heme iron found in the membranes of hemoglobinopathic red blood cells. J Biol Chem 1995; 270: 24876-24883.
2. Ginsburg H, Famin O, Zhang J, Krugliak M. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem Pharmacol 1998; 56: 1305-1313.
3. Schirmer RH, Müller JG, Krauth-Siegel RL. Disulfide reductase inhibitors as chemotherapeutic agents: the design of drugs for trypanosomiasis and malaria. Angew Chem Int Edn 1995; 34: 141-154.
4. Davioud-Charvet E, Delarue S, Biot C et al. A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J Med Chem 2001; 44: 4268-4276.
5. Meierjohann S, Walter RD, Muller S. Regulation of intracellular glutathione levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Biochem J 2002; 368: 761-768.
6. Kanzok SM, Schirmer RH, Turbachova I, Iozef R, Becker K. The thioredoxin system of the malaria parasite Plasmodium falciparum. Glutathione reduction revisited. J Biol Chem 2000; 275: 40180-40186.
7. Farber PM, Arscott LD, Williams Jr CH, Becker K, Schirmer RH. Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Lett 1998; 422: 311-314.
8. Schonleben-Janas A, Kirsch P, Mittl PR, Schirmer RH, Krauth-Siegel RL. Inhibition of human glutathione reductase by 10-arylisoalloxazines: crystalline, kinetic, and electrochemical studies. J Med Chem 1996; 39: 1549-1554.
9. Karplus PA, Pai EF, Schulz GE. A crystallographic study of the glutathione binding site of glutathione reductase at 0.3-nm resolution. Eur J Biochem 1989; 178: 693-703.
10. Salmon-Chemin L, Buisine E, Yardley V et al. 2- and 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. J Med Chem 2001; 44: 548-565.
11. Delarue S, Girault S, Maes L et al. Synthesis and in vitro and in vivo antimalarial activity of new 4-anilinoquinolines. J Med Chem 2001; 44: 2827-2833.
12. Ginsburg H. A double-headed pro-drug that overcomes chloroquine resistance. Trends Parasitol 2002; 18: 103.
13. Krnajski Z, Gilberger TW, Walter RD, Cowman AF, Muller S. Thioredoxin reductase is essential for the survival of Plasmodium falciparum erythrocytic stages. J Biol Chem 2002; 277: 25970-25975.
14. Krauth-Siegel RL, Coombs GH. Enzymes of parasite thiol metabolism as drug targets. Parasitol Today 1999; 15: 404-409.
15. Dessolin J, Biot C, Davioud-Charvet E. Bromination studies of the 2,3-dimethylnaphthazarin core allowing easy access to naphthazarin derivatives. J Org Chem 2001; 66: 5616-5619.
16. Irmler A, Bechthold A, Davioud-Charvet E et al. Disulfide reductases - current developments. In: Chapman SK, Perham RN, Scrutton NS. (eds) Flavins and Flavoproteins 2002. Berlin: Agency for Scientific Publications, 2002; 803-815.
17. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 46: 3-26.
18. Viswanadhan VN, Balan C, Hulme C, Cheetham JC, Sun Y. Knowledge-based approaches in the design and selection of compound libraries for drug discovery. Curr Opin Drug Discov Devel 2002; 5: 400-406.
19. Atamna H, Krugliak M, Shalmiev G, Deharo E, Pescarmona G, Ginsburg H. Mode of antimalarial effect of methylene blue and some of its analogues on Plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoelii nigeriensis in vivo. Biochem Pharmacol 1996; 51: 693-700.
20. Biot C, Bauer H, Schirmer H, Davioud-Charvet E. Carboxylic acid surrogates and prodrugs of Plasmodium falciparum glutathione reductase inhibitors: Synthesis of 5-substituted tetrazoles, bioisosterism and mechanistic studies. Unpublished results